Endometrial Hyperplasia Classification and EIN Guide \| MDster show = false, 1500)" role="region" aria-label="Connection status" aria-atomic="true" x-bind:aria-live="offline ? 'assertive' : 'polite'" x-bind:aria-hidden="(!show).toString()" class="offline-banner max-w-sm mx-auto px-4 py-3 text-sm font-bold text-center text-white rounded-full shadow-lg transition-all duration-500 ease-in-out" :class="{ 'hidden-state': !show, 'bg-error': offline, 'bg-success': !offline }"> You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Neurology ](https://mdster.com/speciality/neurology) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Neurology ](https://mdster.com/speciality/neurology) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Endometrial Hyperplasia Classification: When Atypia Changes Care [ Medical Education ](https://mdster.com/blog?category=medical-education) Endometrial Hyperplasia Classification: When Atypia Changes Care ================================================================== A practical way to distinguish estrogen-driven hyperplasia from EIN and act on the difference. [ MDster Editorial Team ](https://mdster.com/about) · Nov 02, 2026 · 5 min read · 65 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) \| [Corrections Policy](https://mdster.com/corrections) [ Obstetrics & Gynecology ](https://mdster.com/blog?tag=obstetrics-gynecology) [ Abnormal Uterine Bleeding ](https://mdster.com/blog?tag=abnormal-uterine-bleeding) [ Gynecologic Oncology ](https://mdster.com/blog?tag=gynecologic-oncology) [ Endometrial Pathology ](https://mdster.com/blog?tag=endometrial-pathology) [ EIN ](https://mdster.com/blog?tag=ein) ![Endometrial Hyperplasia Classification: When Atypia Changes Care](https://mdster.com/storage/blog/images/endometrial-hyperplasia-classification-when-atypia-changes-care.png) Share this article Share this post On this page 1. [ Classify the lesion before choosing treatment ](#classify-the-lesion-before-choosing-treatment) 2. [ The two categories that matter ](#the-two-categories-that-matter) 3. [ Why unopposed estrogen starts the problem ](#why-unopposed-estrogen-starts-the-problem) 4. [ Think in terms of missing progesterone ](#think-in-terms-of-missing-progesterone) 5. [ Separate future progression from cancer already present ](#separate-future-progression-from-cancer-already-present) 6. [ Two risks, two different conversations ](#two-risks-two-different-conversations) 7. [ Make surveillance match the diagnosis ](#make-surveillance-match-the-diagnosis) 8. [ A biopsy is a decision point, not the finish line ](#a-biopsy-is-a-decision-point-not-the-finish-line) 9. [ Key Takeaways ](#key-takeaways) 10. [ Frequently Asked Questions ](#blog-faqs) 11. [ References ](#references-heading) On this page 1. [ Classify the lesion before choosing treatment ](#classify-the-lesion-before-choosing-treatment) 2. [ The two categories that matter ](#the-two-categories-that-matter) 3. [ Why unopposed estrogen starts the problem ](#why-unopposed-estrogen-starts-the-problem) 4. [ Think in terms of missing progesterone ](#think-in-terms-of-missing-progesterone) 5. [ Separate future progression from cancer already present ](#separate-future-progression-from-cancer-already-present) 6. [ Two risks, two different conversations ](#two-risks-two-different-conversations) 7. [ Make surveillance match the diagnosis ](#make-surveillance-match-the-diagnosis) 8. [ A biopsy is a decision point, not the finish line ](#a-biopsy-is-a-decision-point-not-the-finish-line) 9. [ Key Takeaways ](#key-takeaways) 10. [ Frequently Asked Questions ](#blog-faqs) 11. [ References ](#references-heading) A patient with irregular bleeding and PCOS has an endometrial biopsy reported as “hyperplasia.” Before discussing treatment, read the rest of the report. **Without atypia** and **atypical hyperplasia/EIN** are not minor variations of the same diagnosis: one usually responds to progestin; the other may coexist with carcinoma. [\[1\]](#cite-1 "Reference [1]") Classify the lesion before choosing treatment --------------------------------------------- ### The two categories that matter Modern WHO classification separates endometrial hyperplasia without atypia from atypical hyperplasia, also called endometrial intraepithelial neoplasia (EIN). The older labels “simple” and “complex” describe gland architecture but do not drive decisions as reliably as the presence of atypia. ACOG accepts either *atypical hyperplasia* or *EIN* terminology; ask what the pathologist means if a report uses older language. [\[1\]](#cite-1 "Reference [1]") Biopsy categoryWhat it signalsUsual clinical directionHyperplasia without atypiaCrowded, irregular glands without significant cytologic atypiaAddress estrogen exposure; consider progestin and biopsy surveillanceAtypical hyperplasia/EINCrowded glands with cytology distinct from background endometrium; a precancerous lesionAssess for concurrent cancer; hysterectomy is definitive, or use progestin with close surveillance when appropriate The distinction is not simply “more glands versus fewer glands.” EIN represents a neoplastic precursor to endometrioid carcinoma, whereas hyperplasia without atypia commonly reflects a broader tissue response to sustained estrogen stimulation. Histology—not endometrial thickness on ultrasound—establishes which category is present. [\[1\]](#cite-1 "Reference [1]") > **Clinical Pearl:** If the biopsy says EIN, do not reassure a patient that the finding is “just a thick lining.” First consider whether carcinoma was missed in the sampled tissue. [\[1\]](#cite-1 "Reference [1]") Why unopposed estrogen starts the problem ----------------------------------------- ### Think in terms of missing progesterone Estrogen promotes endometrial proliferation. After ovulation, progesterone counterbalances that growth and supports secretory differentiation; with chronic anovulation, that progesterone exposure is absent. The endometrium remains proliferative, increasing the opportunity for glandular crowding and, in some patients, emergence of a precancerous clone. **Unopposed estrogen explains the setting; it does not tell you the biopsy category.** [\[1\]](#cite-1 "Reference [1]") When reviewing abnormal uterine bleeding (AUB), actively look for the source of exposure: - PCOS or perimenopausal anovulation: cycles may occur without sustained luteal progesterone. - Obesity: extraovarian estrogen production contributes to stimulation, including after menopause. - Systemic estrogen therapy without adequate progestin in a patient with a uterus: the exposure is avoidable. - Tamoxifen: despite its breast effects, it can stimulate the endometrium; review treatment decisions with the prescribing oncology team. [\[2\]](#cite-2 "Reference [2]") Do not assume that correcting the hormone exposure erases an established EIN lesion. Identify the cause, but let tissue diagnosis determine the urgency of cancer assessment and follow-up. [\[1\]](#cite-1 "Reference [1]") Separate future progression from cancer already present ------------------------------------------------------- ### Two risks, two different conversations For hyperplasia **without atypia**, the estimated risk of progression to endometrial cancer is less than 5% over 20 years, and many lesions regress. Progestin improves regression compared with observation alone; observation with repeat biopsies can be reasonable for selected patients whose reversible risk factors are addressed. Persistent AUB or failure to regress favors treatment rather than reassurance. [\[3\]](#cite-3 "Reference [3]") EIN/atypical hyperplasia warrants a different conversation. ACOG reports **concurrent carcinoma in approximately 30–50%** of hysterectomy specimens after an EIN/atypical hyperplasia diagnosis. That figure describes cancer already present but not identified in the initial sample—not the chance that EIN will progress next year. Progression risk is also substantial, but keep those two risks separate when counseling or answering board questions. [\[1\]](#cite-1 "Reference [1]") Make surveillance match the diagnosis ------------------------------------- ### A biopsy is a decision point, not the finish line For hyperplasia without atypia, address modifiable estrogen exposure and offer progestin, particularly when bleeding persists. The levonorgestrel intrauterine system is a first-line medical option in RCOG guidance. Arrange repeat endometrial biopsy at approximately six-month intervals; that guidance recommends two consecutive negative six-monthly biopsies before discharge, with longer follow-up considered for patients at higher relapse risk. [\[3\]](#cite-3 "Reference [3]") For EIN/atypical hyperplasia, **total hysterectomy is definitive treatment** when appropriate. If fertility preservation is desired or surgery is unsuitable, attempt to exclude concurrent carcinoma before conservative treatment; hysteroscopic evaluation with additional sampling is particularly useful when a focal lesion or inadequate sampling is a concern. Use progestin therapy rather than observation alone, and repeat histologic assessment within **3–6 months** to check for persistence or progression. [\[1\]](#cite-1 "Reference [1]") A quieter bleeding pattern is welcome, but it does not prove histologic regression. If bleeding recurs, tissue remains atypical, or sampling is nondiagnostic, reassess rather than extending reassurance indefinitely. Avoid endometrial ablation for EIN: it does not reliably eliminate the lesion and can obstruct future tissue surveillance. [\[1\]](#cite-1 "Reference [1]") Key Takeaways ------------- - Classify by **atypia**, not the old simple-versus-complex terminology. - Recognize EIN/atypical hyperplasia as a precancerous diagnosis with a substantial risk of *concurrent* carcinoma. - Trace unopposed estrogen to anovulation, obesity, or medication exposure—but confirm the lesion by histology. - Match conservative treatment to scheduled **repeat biopsies**; improvement in bleeding alone is insufficient. The habit to carry into clinic is straightforward: read the pathology wording precisely, distinguish occult cancer from future progression, and never let surveillance become an unplanned omission. Frequently Asked Questions ---------------------------- ### Does complex hyperplasia automatically mean a precancerous lesion? No. “Complex” is older terminology describing gland architecture. Determine whether atypia is present; atypical hyperplasia/EIN is the precancerous category. ### Why assess for cancer before fertility-sparing treatment of EIN? An initial biopsy can miss concurrent carcinoma. ACOG reports carcinoma in approximately 30–50% of hysterectomy specimens after an EIN/atypical hyperplasia diagnosis. [\[1\]](#cite-1 "Reference [1]") ### Can improved bleeding replace a repeat biopsy during progestin treatment? No. Symptom improvement does not establish histologic regression; EIN/atypical hyperplasia requires repeat tissue assessment within 3–6 months. [\[4\]](#cite-4 "Reference [4]") ### Is hysterectomy first-line for hyperplasia without atypia? Generally no. Address risk factors and consider progestin with biopsy surveillance; reserve surgery for selected cases such as progression, persistent disease, or inability to complete treatment or follow-up. [\[3\]](#cite-3 "Reference [3]") References (5) ------------------ 1. 1. [ ACOG Clinical Consensus No. 5. Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia. 2023. ](https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/09/management-of-endometrial-intraepithelial-neoplasia-or-atypical-endometrial-hyperplasia) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ www.acog.org/womens-health/faqs/endometrial-hyperplasia ](https://www.acog.org/womens-health/faqs/endometrial-hyperplasia) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ RCOG/BSGE. Management of Endometrial Hyperplasia. Green-top Guideline No. 67. 2016. ](https://www.rcog.org.uk/media/knmjbj5c/gtg_67_endometrial_hyperplasia.pdf) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ doi.org/10.1097/AOG.0000000000005297 ](https://doi.org/10.1097/AOG.0000000000005297) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ WHO Classification of Tumours: Female Genital Tumours. Endometrial epithelial tumours and precursors. ](https://whobluebooks.iarc.who.int/structures/female-genital-tumours/) Keep going Build confidence in OB/GYN with focused practice -------------------------------------------------- - Labor & delivery + postpartum essentials - Gynecology, screening, and common procedures - Review weak topics and improve faster [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features\*. No commitment. Cancel anytime. \*AI SOE Examiner is limited to 10 cases monthly for Advanced & Bundle subscribers. Explore topics: [ # Obstetrics & Gynecology ](https://mdster.com/blog?tag=obstetrics-gynecology) [ # Abnormal Uterine Bleeding ](https://mdster.com/blog?tag=abnormal-uterine-bleeding) [ # Gynecologic Oncology ](https://mdster.com/blog?tag=gynecologic-oncology) [ # Endometrial Pathology ](https://mdster.com/blog?tag=endometrial-pathology) [ # EIN ](https://mdster.com/blog?tag=ein) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Pediatric After-Death Care and Legal Documentation: A Practical Guide 6 min read Nov 03, 2026 ](https://mdster.com/blog/pediatric-after-death-care-and-legal-documentation-a-practical-guide) [### Anticoagulation Risk–Benefit Balancing in Complex AF and VTE 6 min read Nov 01, 2026 ](https://mdster.com/blog/anticoagulation-risk-benefit-balancing-in-complex-af-and-vte) [### RV Failure Physiology and Treatment in Pulmonary Hypertension 6 min read Oct 31, 2026 ](https://mdster.com/blog/rv-failure-physiology-and-treatment-in-pulmonary-hypertension) Related Posts ------------- [ ![Pediatric After-Death Care and Legal Documentation: A Practical Guide](https://mdster.com/storage/blog/images/pediatric-after-death-care-and-legal-documentation-a-practical-guide.png) Medical Education ### Pediatric After-Death Care and Legal Documentation: A Practical Guide A practical pediatric guide to confirming death, writing a useful record, recognizing medical examiner cases, coordinating donation, and supporting families. 6 min read 0 comments ](https://mdster.com/blog/pediatric-after-death-care-and-legal-documentation-a-practical-guide) [ ![Anticoagulation Risk–Benefit Balancing in Complex AF and VTE](https://mdster.com/storage/blog/images/anticoagulation-risk-benefit-balancing-in-complex-af-and-vte.png) Medical Education ### Anticoagulation Risk–Benefit Balancing in Complex AF and VTE Learn how to weigh stroke or recurrent VTE against bleeding risk, address frailty and falls, and document a safe anticoagulation plan with patients. 6 min read 0 comments ](https://mdster.com/blog/anticoagulation-risk-benefit-balancing-in-complex-af-and-vte) [ ![RV Failure Physiology and Treatment in Pulmonary Hypertension](https://mdster.com/storage/blog/images/rv-failure-physiology-and-treatment-in-pulmonary-hypertension.png) Medical Education ### RV Failure Physiology and Treatment in Pulmonary Hypertension In pulmonary hypertension, the failing RV needs more than fluids or a higher blood pressure. Learn how to manage hypoxia, acidosis, congestion, and low cardiac output. 6 min read 0 comments ](https://mdster.com/blog/rv-failure-physiology-and-treatment-in-pulmonary-hypertension) [ ![Noninvasive Respiratory Support Escalation in Children: When to Intubate](https://mdster.com/storage/blog/images/noninvasive-respiratory-support-escalation-in-children-when-to-intubate.png) Medical Education ### Noninvasive Respiratory Support Escalation in Children: When to Intubate A practical pediatric approach to choosing HFNC, CPAP, or BiPAP, recognizing treatment failure early, and preventing interface complications. 6 min read 0 comments ](https://mdster.com/blog/noninvasive-respiratory-support-escalation-in-children-when-to-intubate) [ ![Hereditary Syndromes in Gyn Oncology: BRCA, Lynch, and Surgery](https://mdster.com/storage/blog/images/hereditary-syndromes-in-gyn-oncology-brca-lynch-and-surgery.png) Medical Education ### Hereditary Syndromes in Gyn Oncology: BRCA, Lynch, and Surgery Learn how BRCA1/2 and Lynch syndrome change gynecologic cancer prevention, including genetic evaluation, gene-specific surgery timing, and counseling pitfalls. 5 min read 0 comments ](https://mdster.com/blog/hereditary-syndromes-in-gyn-oncology-brca-lynch-and-surgery) [ ![Atopic Dermatitis and Chronic Urticaria: A Primary Care Guide](https://mdster.com/storage/blog/images/atopic-dermatitis-and-chronic-urticaria-a-primary-care-guide.png) Medical Education ### Atopic Dermatitis and Chronic Urticaria: A Primary Care Guide A practical Family Medicine approach to eczema and chronic hives: choose emollients, topical steroid potency, and antihistamines while spotting infection and referral red flags. 6 min read 0 comments ](https://mdster.com/blog/atopic-dermatitis-and-chronic-urticaria-a-primary-care-guide) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ Download on the App Store ](https://apps.apple.com/app/id6759168258) [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Curriculum](https://mdster.com/curriculum) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) [ ](https://apps.apple.com/app/id6759168258) [ ](https://play.google.com/store/apps/details?id=com.mdster.app) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept